Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MARVEL trial of concurrent radiation, gemcitabine + cisplatin, and durvalumab for advanced biliary tract cancer
jRCTs031230380Phase 1Active, not recruiting
- Sponsor
- Japan Oncology Network in Hepatobiliary and Pancreas
- Start
- Nov 2023
- Modality
- Small Molecules, PD-1/PD-L1 Inhibitors → Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of durvalumab, gemcitabine and cisplatin in biliary cancer and biliary adenocarcinoma, sponsored by Japan Oncology Network in Hepatobiliary and Pancreas. Primary endpoints: Severe treatment-related adverse events and Objective response rate. Started Nov 2023; status: active, not recruiting.
02
Drugs
durvalumabgemcitabinecisplatin
03
Conditions
biliary cancerbiliary adenocarcinoma
Beyond the preview
Go deeper on jRCTs031230380.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs031230380.